Published in Br J Pharmacol on July 01, 1979
Atypical characteristics of the beta-adrenoceptor mediating cyclic AMP generation and lipolysis in the rat adipocyte. Br J Pharmacol (1985) 1.10
Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol (1981) 1.00
Autoradiographic localization of beta-adrenoceptor subtypes in guinea-pig kidney. Br J Pharmacol (1985) 0.93
The role of alpha- and beta-adrenoceptor subtypes in mediating the effects of catecholamines on fasting glucose and insulin concentrations in the rat. Br J Pharmacol (1990) 0.89
Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man. Br J Clin Pharmacol (1980) 0.84
Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers. Br J Clin Pharmacol (1980) 0.83
Autoradiographic analysis of the distribution of beta-adrenoceptors in the dog splenic vasculature. Br J Pharmacol (1986) 0.80
The affinity of betaxolol, a beta 1-adrenoceptor-selective blocking agent, for beta-adrenoceptors in the bovine trachea and heart. Br J Pharmacol (1993) 0.79
Influence of environmental temperature and humidity on bronchial responses during assessment of selectivity of beta-adrenoceptor antagonists in man. Br J Clin Pharmacol (1981) 0.75
Proceedings of the British Pharmacological Society. London, 17th-19th December, 1984. Abstracts. Br J Pharmacol (1985) 0.75
Studies on RX 781094: a selective, potent and specific antagonist of alpha 2-adrenoceptors. Br J Pharmacol (1983) 2.21
Action of -adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine. Arzneimittelforschung (1973) 1.71
The potassium channel opener cromakalim (BRL 34915) activates ATP-dependent K+ channels in isolated cardiac myocytes. Biochem Biophys Res Commun (1988) 1.65
Central alpha- and beta-adrenoceptors modifying arterial blood pressure and heart rate in conscious cats. Br J Pharmacol (1974) 1.62
Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol (1974) 1.40
A technique for recording sympathetic nerve activity in unanaesthetized dogs. Neuropharmacology (1974) 1.38
Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol (2008) 1.28
Tissue levels of several radiolabelled beta-adrenoceptor antagonists after intravenous administration in rats. Arch Int Pharmacodyn Ther (1979) 1.25
Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch Pharmacol (1984) 1.21
Differential effects of prazosin on the pre- and postsynaptic alpha-adrenoceptors in the rat and dog [proceedings]. Br J Pharmacol (1977) 1.15
Effects of prazosin and phentolamine on cardiac presynaptic alpha-adrenoceptors in the cat, dog and rat. Clin Exp Hypertens (1978) 1.15
Studies on the mechanism of the vasodilator effects of prazosin in dogs and rabbits. Eur J Pharmacol (1978) 1.13
alpha 2-Adrenoceptor agonists induced mydriasis in the rat by an action within the central nervous system. Br J Pharmacol (1983) 1.11
Cardiovascular effects of beta-adrenoreceptor blocking agents after intracerebroventricular administration in conscious normotensive cats. Clin Exp Pharmacol Physiol (1975) 1.10
Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol (1998) 1.09
Cardiovascular effects of prazosin in dogs. Clin Sci Mol Med Suppl (1976) 1.09
Potassium channel openers act through an activation of ATP-sensitive K+ channels in guinea-pig cardiac myocytes. Pflugers Arch (1989) 1.07
Chromium availability in ultramafic soils from New Caledonia. Sci Total Environ (2003) 1.06
The pharmacology of prazosin, a novel antihypertensive agent. Life Sci (1980) 1.03
Cardiovascular characterization of DA-1 and DA-2 dopamine receptor agonists in anesthetized rats. Clin Exp Hypertens A (1987) 1.01
Central adrenoreceptors and the control of arterial blood pressure. Clin Exp Pharmacol Physiol (1975) 1.00
Urethane inhibits cardiovascular responses mediated by the stimulation of alpha-2 adrenoceptors in the rat. J Pharmacol Exp Ther (1982) 1.00
Adrenoceptors in the central nervous system concerned with cardiovascular control. J Pharm Pharmacol (1972) 0.99
Chemokine production by human vascular smooth muscle cells: modulation by IL-13. Br J Pharmacol (1997) 0.99
Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation (1992) 0.99
-Adrenergic receptors in the central nervous system of the cat concerned with control of arterial blood pressure and heart rate. Nat New Biol (1973) 0.98
The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther (1991) 0.98
Presynaptic alpha-adrenoreceptors; in vitro methods and preparations utilised in the evaluation of agonists and antagonists. J Auton Pharmacol (1980) 0.96
Characterization of alpha-adrenoceptors in the vasculature of the canine nasal mucosa. Br J Pharmacol (1986) 0.95
Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part I: Subclassification and functional description. Life Sci (1982) 0.95
K+ channel openers and 'natural' cardioprotection. Trends Pharmacol Sci (1992) 0.95
In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. Arzneimittelforschung (1995) 0.95
"Calcium antagonists": a class of drugs with a bright future. Part II. Determination of basic pharmacological properties. Life Sci (1984) 0.95
Vasodilator activity of endothelin-1 and endothelin-3: rapid development of cross-tachyphylaxis and dependence on the rate of endothelin administration. J Pharmacol Exp Ther (1990) 0.93
Cellular pharmacology of potassium channel openers in vascular smooth muscle. Cardiovasc Res (1994) 0.93
Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. J Pharmacol Exp Ther (1990) 0.93
The effects of prazosin on the clonidine induced hypotension and bradycardia in rats and sedation in chicks [proceedings]. Br J Pharmacol (1978) 0.92
Time-course analysis of the cardiovascular effects of clonidine resulting from the activation of cardiac pre- and vascular postsynaptic alpha-adrenoceptors in the pithed rat [proceedings]. Br J Pharmacol (1978) 0.92
Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol (1992) 0.91
Selectivity and potency of 2-alkyl analogues of the alpha 2-adrenoceptor antagonist idazoxan (RX 781094) in peripheral systems. Br J Pharmacol (1984) 0.91
The mechanism of the antihypertensive action of -methyldopa in hypertensive rats. Eur J Pharmacol (1973) 0.91
Studies on the bradycardia induced by (-)- -trans-tetrahydrocannabinol in anesthetized dogs. Eur J Pharmacol (1973) 0.91
Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol. J Pharmacol Exp Ther (1987) 0.90
Systemic and regional hemodynamic characterization of alpha-1 and alpha-2 adrenoceptor agonists in pithed rats. J Pharmacol Exp Ther (1987) 0.89
"Calcium antagonists": a class of drugs with a bright future. Part I. Cellular calcium homeostasis and calcium as a coupling messenger. Life Sci (1983) 0.89
Effects of mianserin, desipramine and maprotiline on blood pressure responses evoked by acetylcholine, histamine and 5-hydroxytryptamine in rats. Br J Pharmacol (1981) 0.89
Studies on the rebound hypertension after clonidine withdrawal in conscious hypertensive cats, rats, and dogs [proceedings]. Br J Pharmacol (1977) 0.89
High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation. Mol Pharmacol (1988) 0.89
Rat juxtaglomerular cells are endowed with DA-1 dopamine receptors mediating renin release. J Cardiovasc Pharmacol (1988) 0.88
Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension (1980) 0.88
Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol (1993) 0.88
Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics. Fundam Clin Pharmacol (2000) 0.88
New evidence for an -andrenergic component in the sympathetic centres: centrally mediated decrease in sympathetic tone by L-dopa and its antagonism by piperoxane and yohimbine. Eur J Pharmacol (1972) 0.88
Nicorandil: differential contribution of K+ channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin. J Pharmacol Exp Ther (1991) 0.88
Diltiazem protects the isolated rabbit heart from the mechanical and ultrastructural damage produced by transient hypoxia, low-flow ischemia and exposure to Ca++-free medium. J Pharmacol Exp Ther (1983) 0.87
RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release. J Lipid Mediat (1992) 0.87
The contribution of guanylate cyclase stimulation and K+ channel opening to nicorandil-induced vasorelaxation depends on the conduit vessel and on the nature of the spasmogen. J Pharmacol Exp Ther (1994) 0.87
Hemodynamic and myocardial effects of (-)-delta9-trans-tetrahydrocannabinol in anesthetized dogs. Eur J Pharmacol (1973) 0.87
Endothelin--a new family of endothelium-derived peptides with widespread biological properties. Life Sci (1989) 0.87
Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sci (1990) 0.86
Vascular beta-adrenoceptor stimulating properties of phenylephrine. Eur J Pharmacol (1977) 0.86
[Effect of sympathomimetics on the vasomotor centers]. Arch Int Pharmacodyn Ther (1971) 0.85
Influence of depolarization on vasorelaxant potency and efficacy of Ca2+ entry blockers, K+ channel openers, nitrate derivatives, salbutamol and papaverine in rat aortic rings. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.85
Indoline analogues of idazoxan: potent alpha 2-antagonists and alpha 1-agonists. J Med Chem (1988) 0.85
RP 58866 and its active enantiomer RP 62719 (terikalant): blockers of the inward rectifier K+ current acting as pure class III antiarrhythmic agents. J Cardiovasc Pharmacol (1992) 0.84
Regional distribution and pharmacological characterization of [125I]endothelin-1 binding sites in human fetal placental vessels. Placenta (1991) 0.84
Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor stimulant properties of cirazoline (LD 3098), a potent alpha-1 adrenoceptor agonist in dogs and rats. J Pharmacol Exp Ther (1982) 0.84
Increase in plasma renin activity evoked by fenoldopam in dogs is directly mediated by dopamine1 receptor stimulation. J Cardiovasc Pharmacol (1989) 0.84
Inhibition of platelet adhesion to fibrin(ogen) in flowing whole blood by Arg-Gly-Asp and fibrinogen gamma-chain carboxy terminal peptides. Thromb Haemost (1992) 0.84
Effects of Ca2+ antagonists and K+-channel activators on K+-induced contractions in the rat aorta. J Auton Pharmacol (1989) 0.84
Differential inhibition of vascular smooth muscle responses to alpha 1- and alpha 2-adrenoceptor agonists by diltiazem and verapamil. Circ Res (1983) 0.84
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants. J Med Chem (1983) 0.83
Effects of clonidine, prazosin and phentolamine on heart rate and coronary sinus catecholamine concentration during cardioaccelerator nerve stimulation in spinal dogs. Br J Pharmacol (1979) 0.83
Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. Am J Physiol (1997) 0.83
Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats. J Pharmacol Exp Ther (1991) 0.82
Alpha-adrenoreceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on alpha-adrenoreceptor activity. J Med Chem (1984) 0.82
Decrease in the sympatho-inhibitory action of clonidine after destruction of the sympatho-inhibitory area. Experientia (1973) 0.82
The blood pressure lowering effects of intravenous versus intracerebroventricular prazosin in anaesthetised cats. Eur J Pharmacol (1978) 0.82
Activation of cardiac KATP channels: an endogenous protective mechanism during repetitive ischemia. Am J Physiol (1993) 0.82